Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Dr Desai on the Treatment Landscape of Polycythemia Vera

November 14th 2025

Ruchi J. Desai, MD, discusses the treatment landscape of polycythemia vera and unmet needs in the space.

Dr Saad on the Rationale for AI-Generated Synthetic Cohorts in Metastatic Breast Cancer Research

November 14th 2025

Eddy Saad, MD, discusses how AI-generated synthetic cohorts derived from real-world data may accelerate trial design and collaboration in metastatic breast cancer.

Phase 3 Data Illuminate Advancing Roles for T-DXd and Combination Approaches in HER2+ Breast Cancer

November 14th 2025

Yuan Yuan, MD, PhD, expands on several key studies informing the current and evolving use of ADCs and dual-pathway targeting in HER2-positive breast cancer.

Post-Operative Lymphatic ctDNA Data Shows Superior Sensitivity for Detecting Residual Disease in HPV-Independent HNSCC

November 14th 2025

Post-operative lymphatic ctDNA results exceeded plasma assays in detecting residual disease and predicting recurrence in HPV-independent HNSCC.

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

November 14th 2025

Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.

Community Administration of Bispecific Antibodies in Myeloma Hinges on Consensus and Guidance

November 13th 2025

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Dr Tagawa on the Safety Profile of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

November 12th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the safety profile of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Raab on the Rationale for Adding Teclistamab to Daratumumab-Based Induction in NDMM

November 12th 2025

Marc S. Raab, MD, discusses the rationale for assessing teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Sequential CAR T-Cell Therapy and ASCT Yields Durable Remissions in Ph-Negative B-ALL

November 12th 2025

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

Dr Saeed on the Rationale for Evaluating the Combination of Zanzalintinib Plus Atezolizumab vs Regorafenib in mCRC

November 11th 2025

Anwar Saeed, MD, discusses the rationale behind the STELLAR-303 trial evaluating zanzalintinib plus atezolizumab vs regorafenib in pretreated mCRC

CONGRATS Trial Data of Nivolumab ± Relatlimab Highlight Clinical Value of Immunotherapy in TLS+ Soft Tissue Sarcoma

November 11th 2025

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

FDA Approves OncoMate MSI Dx as Companion Diagnostic for Pembrolizumab/Lenvatinib in MSS Endometrial Cancer

November 11th 2025

OncoMate MSI Dx was approved by the FDA to identify patients with MSS endometrial cancer who may be eligible for pembrolizumab plus lenvatinib.

Detalimogene Produces 63% CR Rate in BCG-Unresponsive NMIBC with CIS

November 11th 2025

Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

Precision Survivorship Platforms Are Essential for Improved, Equitable Care in Pediatric and AYA Sarcoma

November 11th 2025

R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.

At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma

November 11th 2025

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

Zanzalintinib Plus Atezolizumab Signals New Progress for Previously Treated mCRC

November 10th 2025

Anwar Saeed, MD, discusses findings of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

Darovasertib Plus Crizotinib Could Represent Systemic Therapy Intended for Broader Metastatic Uveal Melanoma Population

November 7th 2025

Marlana Orloff, MD, discusses data for the combination of darovasertib and crizotinib in metastatic uveal melanoma.

BVd Approval Reframes Considerations Around Sequencing BCMA-Targeted Therapies in R/R Myeloma

November 7th 2025

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

Dr Wang on the Safety Profile of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

November 6th 2025

Pule Wang, MD, discusses safety data with CNS bridging radiotherapy before CAR T in B-cell lymphoma.

Dr Tagawa on the Efficacy of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

November 6th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the efficacy of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.